SCIT Versus SLIT: Which One Do You Recommend, Doc?

Special FeaturePatient-Centered Focused ReviewSCIT Versus SLIT: Which One Do You Recommend, Doc?Author links open overlay panel

Mohamad R.ChaabanMD, MSCR, MBA1AhmedMansiBSc2Julia W.TrippleMD3Sarah K.WiseMD4

The American Journal of the Medical Sciences

Volume 357, Issue 5, May 2019, Pages 442-447

Abstract

Allergic rhinitis is a prevalent condition that has a significant impact on the quality of life of many patients. When initial therapy fails to control the symptoms, allergen immunotherapy (AIT) has been suggested as an option by the Joint Task Force on Practice Parameters.

The 2 main forms of AIT are via subcutaneous and sublingual routes, called subcutaneous immunotherapy and sublingual immunotherapy, respectively. There is debate about which is the better option for patients with each method offering its own pros and cons. We present 2 patients with allergic rhinitis (AR) that were deemed good candidates for AIT and explore current evidence for both subcutaneous immunotherapy and sublingual immunotherapy. The advantages and disadvantages of each method are discussed with the goal of providing a framework for the physician when deciding on AIT for their patients. In addition, we explore the use of AIT in patients with asthma and atopic dermatitis as potential patient populations that may benefit from the treatment. We use the discussion to provide recommendations regarding which method of AIT is best suited for both our patients.

Download PDF